Rousselot Biomedical

Rousselot Biomedical - advancing medical science

A strategic business segment within Rousselot® - the world-leading manufacturer of collagen-based solutions – Rousselot Biomedical has drawn upon 130 years of worldwide expertise and proven track record of pharmaceutical gelatins and collagens to develop innovative ranges of purified, modified and non-modified gelatins and collagens for biomedical applications.

X-Pure®: A world-class range of customizable low-endotoxin gelatins and collagens for in vitro and in vivo applications
X-Pure® is a range of low-endotoxin, customizable, pharmaceutical-grade gelatins designed to ensure maximum quality and safety. The range comprises various gelatins and modified gelatins, namely X-Pure, X-Pure GelMA, and X-Pure GelDAT. Notably X-Pure GelMA is the world’s first gelatin methacryloyl produced under GMP conditions.

The ultra-purified and modified gelatins within the X-Pure range find application in diverse fields such as regenerative medicine, drug delivery, embolization, and hemostasis projects.

New Quali-Pure® range of pharmaceutical gelatins
Specifically designed to support biomedical application areas including embolization, wound healing, drug delivery, vaccines and hemostatics, Quali-Pure® delivers biocompatibility, biodegradability, controlled endotoxin levels, and batch-to-batch consistency.

All Rousselot biomedical gelatins are GMP* ready and fully documented to support medical device compliance with ISO standards and the new EU Medical Device Regulation (MDR).

Rousselot’s research and GMP grades are functionally equivalent, streamlining the transition from research to clinical trials by minimizing the necessity for data revalidation.

Rousselot Biomedical is committed to engineering, accelerating and scaling superior products to help transform ideas into biomedical solutions worldwide, using our scientific expertise and collaborative approach to support end-to-end partnerships and to “Improve patients’ lives”.

* IPEC & PQG Joint Good Manufacturing Practices Guide for Pharmaceutical Excipients

Rousselot BV
Kanaaldijk Noord 20
5691 NM SON
The Netherlands
Phone: +31 499 364100

For more information please visit: www.rousselot.com/biomedical

White Papers

The unique properties of gelatin in 3D bioprinting

The mutiple benefits of highly purified gelatins in parenteral applications

Gelatin for safe micro- and submicron particle applications

Rousselot low endotoxin gelatins and collagens for biomedical applications

Videos

No more batch lottery when making a new GelMA

X-Pure – Bridging the valley of death

For ultra-low endotoxin biomaterial, choose X-Pure

Press Releases

New Study Shows Low Endotoxin Biomaterials Improve Reliability of 3D In Vitro Models; Pave the Way for Reduced Animal Testing

Irving, United States, 15th March 2023 / Sciad Newswire / Darling Ingredients’ health brand Rousselot, the global leader1 in collagen-based solutions, announced today that a new study has found that utilization of highly purified gelatin biomaterials for 3D in vitro models can significantly enhance the reliability and reproducibility in these models, creating new possibilities for replacing preclinical animal trials.

16 March 2023

Gelomics Partners With Rousselot Biomedical to Create the World’s First, Ready-to-Use 3D Cell Culture Kits Based on X-PURE® GelMA

Irving, United States, 16th November 2022 / Sciad Newswire / Darling Ingredients’ Health Brand, Rousselot, the global leader in collagen-based solutions, and Gelomics, the world-leading provider of fully integrated 3D cell, organoid and tissue culture technologies, have entered into a cobranding partnership. Rousselot Biomedical will supply Gelomics with its X-Pure GelMA (gelatin methacryloyl), a photo cross-linkable extracellular matrix, for use in Gelomics’ LunaGel™ 3D Tissue Culture System.

22 November 2022

Rousselot® Biomedical announces the launch of Quali-Pure HGP 2000

Irving, United States, May 4 2022 / Sciad Newswire / Rousselot®, Darling Ingredients’ health brand and the global leader of collagen-based solutions1, launches Quali-Pure™ HGP 2000, a new endotoxin-controlled, pharmaceutical-grade gelatin specifically designed for vaccines and wound healing applications. As the latest addition to Rousselot Biomedical’s rapidly expanding product offering, this new non-gelling hydrolyzed gelatin further extends the scope of biomedical applications covered by Rousselot products.

4 May 2022

Rousselot Biomedical announces the world’s first GelMA produced under GMP

Irving, United States, 13th April 2022 / Sciad Newswire / Rousselot®, Darling Ingredients’ health brand, and the global leader of collagen-based solutions1 announces the launch of GMP grade GelMA. X-Pure® GelMA is the first gelatin methacryloyl, or GelMA, on the market to be produced under GMP conditions2.

14 April 2022

Products & services

X-Pure® Gelatins

X-Pure® is a range of premium-grade gelatins, with tunable functionalities in addition to high-purity ≤10EU/g. X-Pure gelatins are optimized for in-vivo or in-vitro research and clinical applications and produced under GMP conditions. They can be designed or customized to provide significant technical advantages for the development of biomedical applications.

X-Pure® GelMA

Due to its excellent biocompatibility, biodegradability, and tunability, Gelatin methacryloyl (GelMA) is probably the most popular biomaterial used in 3D bioprinting, tissue engineering and 3D cell culture applications.

X-Pure® GelDAT®

X-Pure® GelDAT is the world’s first purified Gelatin Desaminotyrosine. X-Pure GelDAT hydrogels are ideal for research and preclinical development in regenerative medicine, drug release and complex wound dressings due to their ability to crosslink with tissues and their purity.

Quali-Pure® range of pharmaceutical gelatins

Quali-Pure® is a range of pharmaceutical gelatins, that has been specifically designed to support biomedical application areas including embolization, wound healing, drug delivery, vaccines and hemostatics.

Subscribed

Rousselot Biomedical - advancing medical science